跳至主要内容
临床试验/CTRI/2019/02/017690
CTRI/2019/02/017690
招募中
3 期

A randomized single blind, placebo control clinical study to evaluate the efficacy of Dalbergia sissoo extract (Dalzbone capsule) in healing of diaphyseal fracture of femur - DSFFCT

Pharmanza Herbal Pvt Ltd0 个研究点目标入组 0 人待定

概览

阶段
3 期
干预措施
未指定
疾病 / 适应症
Health Condition 1: S723- Fracture of shaft of femur
发起方
Pharmanza Herbal Pvt Ltd
状态
招募中
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional

研究者

入排标准

入选标准

  • 1\. Radiologically diagnosed traumatic diaphyseal fracture of femur bone indifferent of compound, comminuted, closed or open fracture with surgical intervention.
  • 2\. Willing to give informed consent.
  • 3\. 0\-5 days from the incident of fracture.

排除标准

  • 1\. Pathological fracture.
  • 2\. Fracture patients with uncontrolled HTN(Blood Pressure \>\=140 mmHg or an average Diastolic Blood Pressure \>\=90 mmHg among those with HTN) or diabetes (Blood Glucose Level \> 200 and Fasting Blood Glucose Level \> 125 among those with diabetes)
  • 3\. Fracture in smokers.
  • 4\. Pregnant and breast feeding women.
  • 5\. History of allergy to herbal medicines.
  • 6\. Patient with renal failure, liver failure and or cardiac failure.

结局指标

主要结局

未指定

相似试验